# CBD and Recurrent Pericarditis: What the Phase II MAvERIC-Pilot Trial Shows > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-recurrent-pericarditis-maveric-pilot-trial/ > **Published:** 2026-07-12T17:57:19-04:00 | **Last Modified / Clinically Audited:** 2026-10-14T08:57:00-04:00 > **Clinical Summary:** CBD recurrent pericarditis: A Phase II trial of pharmaceutical CBD (CardiolRx) reduced pain and inflammation in 27 recurrent pericarditis patients. Dr. Capla... --- CED Clinical Relevance #81 Strong Clinical Relevance A prospective, though open-label and industry-sponsored, Phase II trial with objective inflammatory biomarker data in a disease with few non-immunosuppressive treatment options. Clinical Insight | CED Clinic A Phase II trial of a pharmaceutical-grade oral CBD formulation, CardiolRx, reports the first prospective human data on cannabidiol in recurrent pericarditis, a disease of repeated pericardial inflammation driven in part by inappropriate NLRP3 inflammasome activation. Across 27 adults treated for eight weeks, average pain scores fell from 5.8 to 2.1, and eight of ten patients with elevated C-reactive protein saw it normalize. Seventy-one percent of patients who entered an 18-week extension phase stayed recurrence-free while background steroids, colchicine, and NSAIDs were tapered and discontinued. The central clinical lesson is not that CBD is now a proven pericarditis therapy, but that a mechanism-targeted, pharmaceutical-grade cannabinoid produced a measurable, biomarker-supported signal worth testing in a controlled trial, which is now underway. PericarditisCBDInflammationCardiologyClinical Trial Audience Patients with recurrent pericarditis, cardiologists, rheumatologists, and cannabis-medicine clinicians fielding questions about pharmaceutical CBD Primary Topic Phase II clinical trial data on pharmaceutical CBD (CardiolRx) for recurrent pericarditis Source [Read the sponsor’s publication announcement](https://www.cardiolrx.com/cardiol-therapeutics-phase-ii-maveric-results-accepted-for-publication-in-the-journal-of-the-american-heart-association/) A Phase II trial of pharmaceutical CBD in patients with recurrent pericarditis reported meaningful reductions in pain and inflammation. Here is what the MAvERIC-Pilot data actually shows, and does not show. What This Study Teaches Us The MAvERIC-Pilot study is an open-label, multicenter Phase II trial testing CardiolRx, a pharmaceutical oral CBD formulation, in adults with symptomatic recurrent pericarditis. It reports pain score reductions, C-reactive protein normalization in most patients with elevated baseline levels, and a majority of patients remaining recurrence-free during a supervised taper off standard background therapy. Why This Matters Recurrent pericarditis has few non-immunosuppressive treatment options, and patients often cycle through corticosteroids, colchicine, and injectable IL-1 inhibitors with real side-effect and dependency tradeoffs. A cannabinoid formulation that targets the NLRP3 inflammasome, the pathway thought to drive much of this disease, offers a mechanistically distinct option worth tracking as it moves into a randomized Phase III trial. Study Snapshot Trial Name MAvERIC-Pilot (Phase II), NCT05494788 Sponsor Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) Design Open-label, multicenter, single-arm, 8 U.S. clinical sites Population 27 adults with symptomatic recurrent pericarditis, average age 53, 67% female Intervention Oral pharmaceutical CBD (CardiolRx), titrated over an 8-week primary period, then an optional 18-week extension with background medication taper Primary Results Pain score 5.8 to 2.1 at 8 weeks; 8 of 10 patients with elevated CRP normalized; 71% (17/24) recurrence-free through the extension Safety One serious adverse event led to discontinuation; otherwise described as safe and generally well tolerated Journal Journal of the American Heart Association (JAHA) Conference Presentation American Heart Association Scientific Sessions 2024 (Circulation, abstract 4140774) DOI 10.1161/JAHA.125.047605 (cited by secondary press coverage; confirm directly on ahajournals.org before further citation) Phase III MAVERIC, randomized double-blind placebo-controlled, NCT06708299, more than 75% enrolled as of mid-2026 Clinical Bottom Line This is real, prospective Phase II data showing a measurable pain and CRP signal in recurrent pericarditis, not proof that CBD works, since there was no placebo arm and the sponsor funded the trial. It is a strong enough signal to justify the randomized Phase III trial now underway, and not yet strong enough to change first-line treatment. The Mechanism: NLRP3 Inflammasome Recurrent pericarditis is increasingly understood as a disease of inappropriate activation of the NLRP3 inflammasome, an intracellular inflammatory pathway. Pharmaceutical CBD has been shown in preclinical work to inhibit this pathway, which is the biological rationale for testing it here, distinct from THC or whole-plant cannabis products. This mechanistic framing matters clinically because it points toward a non-immunosuppressive alternative to corticosteroids and IL-1 inhibitors, rather than a broad anti-inflammatory or psychoactive effect. What Actually Happened in the Trial Twenty-seven adults with chest pain of at least 4 out of 11 and either elevated CRP or imaging evidence of pericardial inflammation were enrolled. Average maximum pain scores fell from 5.8 to 2.1 over 8 weeks, with a median of 5 days to reach a pain score of 2 or lower. Of the 10 patients who entered the trial with elevated CRP, 8 had normal levels by week 8. Of the 24 patients who continued into the 18-week extension, 17 (71%) remained free of another pericarditis flare while NSAIDs, colchicine, and corticosteroids were gradually tapered and stopped. Industry Sponsorship and What It Means Cardiol Therapeutics, the company that manufactures CardiolRx, designed, funded, and ran this trial, and its own investor materials describe the results as validating its ongoing Phase III program. That is a legitimate and disclosed conflict of interest, not a disqualifying one, but it belongs in any honest read of the data. Industry-sponsored, open-label, single-arm pilot trials are a normal and necessary early step in [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/). The appropriate response is not to dismiss the data, but to wait for the blinded, placebo-controlled Phase III trial before treating these numbers as settled. Why the Open-Label Design Limits the Pain Data Recurrent pericarditis pain is known to wax and wane, and patients are typically enrolled at a symptomatic peak, which alone can produce improvement over time. Because every patient and investigator knew CBD was being given, subjective pain reporting in particular is vulnerable to expectation effects. The CRP data is more reassuring because it is an objective, patient-independent biomarker. The recurrence-free rate during the extension is harder to interpret in isolation, since it occurred while background medications were simultaneously being tapered under close monitoring. How Strong Is This Evidence? This is prospective, methodologically transparent Phase II data, a real step above case reports or preclinical work. But it is open-label with no control arm, in a disease known for placebo response and natural symptom fluctuation, so the pain-score improvement cannot be cleanly separated from expectation effects and regression to the mean. The CRP normalization in 8 of 10 patients is the most convincing single data point, since it does not depend on subjective reporting. Where This Paper Deserves Skepticism The trial was designed and funded by the company that manufactures the study drug, and the small sample (n=27) across 8 sites limits how confidently these results generalize. The recurrence-free rate during the extension phase is confounded by the simultaneous, monitored taper of NSAIDs, colchicine, and corticosteroids, so it is difficult to isolate CBD’s independent contribution to that outcome. One serious adverse event occurred in a cohort this size, a signal that needs a larger controlled trial to properly characterize rather than dismiss. What This Paper Does Not Show This trial does not show that CBD is superior to, or interchangeable with, colchicine or IL-1 inhibitors, none of which were compared head-to-head here. It does not establish an effective dose outside the titration protocol used, and it says nothing about whole-plant cannabis, THC-containing products, or over-the-counter CBD of variable purity, which differ pharmacologically and in regulatory oversight from a pharmaceutical-grade, FDA Orphan Drug-designated formulation. It also does not address safety or efficacy beyond 26 weeks. How This Fits With the Broader Clinical Conversation Recurrent pericarditis patients are frequently caught between chronic steroid dependency and biologic therapies with real cost and side-effect tradeoffs, so a mechanistically distinct option deserves serious attention even at an early stage. This trial is also a useful marker for where rigorous cannabinoid [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) is actually happening: pharmaceutical-grade, mechanism-targeted formulations moving through FDA-recognized trial phases, in contrast to the far murkier evidence base behind most consumer [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/). Dr. Caplan’s Take *I find this trial encouraging as a signal, not as an answer. The CRP data is the part I trust most, because it does not rely on what a patient reports feeling.* *I would not tell a pericarditis patient today that CBD is a proven alternative to colchicine or biologic therapy based on 27 open-label patients funded by the drug’s own manufacturer. What I would say is that this is exactly the kind of early, mechanism-driven data that should make us watch the Phase III MAVERIC results closely, and that patients asking about this study need to understand the difference between a pharmaceutical-grade, dose-controlled trial drug and the bottle of tincture on a dispensary shelf.* What a Careful Reader Should Take Away A careful reader should treat this as promising pilot data supporting a real Phase III trial, not as evidence that pharmaceutical CBD is now a validated pericarditis treatment. The CRP signal deserves attention; the pain and recurrence data need the controlled trial to confirm. Evidence Interpretation Guide Table of Contents - [How to Read an Open-Label Pilot Trial Without Overclaiming](#How_to_Read_an_Open-Label_Pilot_Trial_Without_Overclaiming)[From Trial Data to Clinical Caution](#From_Trial_Data_to_Clinical_Caution) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[A Real Signal, Not Yet a Green Light](#A_Real_Signal_Not_Yet_a_Green_Light) - [A Mechanism Worth Tracking, Not Yet a Guideline Change](#A_Mechanism_Worth_Tracking_Not_Yet_a_Guideline_Change) - [Open-Label, Industry-Funded, Small Sample](#Open-Label_Industry-Funded_Small_Sample) - [The Recurrence Data Is Confounded](#The_Recurrence_Data_Is_Confounded) - [Following the Same Path as IL-1 Inhibitors](#Following_the_Same_Path_as_IL-1_Inhibitors) - [Not a Substitute for Colchicine or Biologics Yet](#Not_a_Substitute_for_Colchicine_or_Biologics_Yet) - [The Phase III MAVERIC Trial Is the Real Test](#The_Phase_III_MAVERIC_Trial_Is_the_Real_Test) - [Orphan Drug Status Reflects Unmet Need, Not Proven Efficacy](#Orphan_Drug_Status_Reflects_Unmet_Need_Not_Proven_Efficacy) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Read an Open-Label Pilot Trial Without Overclaiming Early-phase, open-label pilot trials like MAvERIC-Pilot exist to justify a definitive trial, not to replace one. Reading them well means separating the objective signals from the subjective ones. This is also a useful template for evaluating any single-arm cannabinoid trial that circulates in cannabis-medicine circles: what was measured, who funded it, and what comes next. ### From Trial Data to Clinical Caution **Design**Open-label and single-arm means no placebo comparison; results can be influenced by expectation and natural disease fluctuation. **Biomarker vs. symptom**CRP normalization is objective; pain scores in an unblinded trial are more vulnerable to bias. **Funding**An industry-sponsored trial evaluating the sponsor’s own drug is a disclosed conflict of interest to weigh, not a reason to dismiss the data outright. **What’s next**A randomized, double-blind, placebo-controlled Phase III trial (MAVERIC) is already enrolling, which is the right response to pilot data like this. The Question This Trial Was Designed to Answer Does pharmaceutical CBD (CardiolRx) produce a measurable reduction in pain and inflammation in patients with symptomatic recurrent pericarditis, and is it safe enough to justify a definitive [randomized trial](https://cedclinic.com/cannabis-cannabinoids-therapeutic-applications-review/)? The Question Patients Usually Need Answered Is this pharmaceutical trial drug the same as the CBD sold in dispensaries, and is it proven enough to replace my current pericarditis treatment? The Bottom Line It supports moving forward to a controlled trial. It does not yet support replacing established pericarditis therapy. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview The same 27-patient trial reads differently depending on whether you are the patient living with recurrent chest pain, the clinician managing therapy tapers, or the skeptic weighing an industry-funded open-label design. #### A Real Signal, Not Yet a Green Light If you live with recurrent pericarditis, this trial is a reason for cautious hope rather than a reason to ask your doctor to switch you to CBD today. The pain and CRP improvements are real numbers from real patients, but they come from an open trial funded by the drug’s maker. The most useful thing to track if you are curious about cannabinoid options is whether a controlled trial confirms these results, which is exactly what the ongoing Phase III MAVERIC trial is designed to test. Lens takeaway Watch the Phase III results before treating this as settled. #### A Mechanism Worth Tracking, Not Yet a Guideline Change For clinicians managing recurrent pericarditis, this data supports keeping an eye on CardiolRx as it moves through Phase III, without changing first-line practice yet. Colchicine and IL-1 inhibitors remain the therapies with controlled-trial support. The CRP normalization is the number worth discussing with patients who ask about this study, since it is the least subjective part of the result. Lens takeaway Track the Phase III data before any practice change. #### Open-Label, Industry-Funded, Small Sample A skeptical reading starts with who funded and ran this trial: the company that manufactures the drug, evaluating its own product, with no placebo arm and 27 patients. That combination should lower confidence in the pain-score results specifically. None of that makes the trial worthless. It makes it exactly what pilot trials are supposed to be: a rationale for a bigger, controlled trial, not a substitute for one. Lens takeaway Industry-funded open-label pilots earn a follow-up trial, not a conclusion. #### The Recurrence Data Is Confounded The 71% recurrence-free rate during the extension phase is the most clinically appealing number in this trial, and also the hardest to interpret cleanly, because it occurred while background steroids, colchicine, and NSAIDs were simultaneously being tapered under monitoring. Without a comparison group tapering the same medications without CBD, it is not possible to say how much of that outcome belongs to the study drug. Lens takeaway A single-arm taper result needs a comparison arm to mean much. #### Following the Same Path as IL-1 Inhibitors Other recurrent pericarditis therapies, including IL-1 inhibitors like rilonacept, moved through similar open-label pilot data before reaching randomized, placebo-controlled confirmation. CardiolRx appears to be following the same development path. That precedent is reassuring about the process, but it does not shortcut the need for the controlled trial before treating CBD as proven. Lens takeaway This is an early step in a familiar, legitimate drug-development sequence. #### Not a Substitute for Colchicine or Biologics Yet Patients should not stop established recurrent pericarditis therapy in favor of over-the-counter CBD based on this trial. The drug tested was a pharmaceutical-grade, dose-controlled formulation with FDA Orphan Drug designation, not a retail CBD product. Anyone tapering pericarditis medications, with or without CBD, should do so under close medical supervision, exactly as this trial’s protocol required. Lens takeaway This is trial-drug data, not permission to self-manage with dispensary CBD. #### The Phase III MAVERIC Trial Is the Real Test The pivotal Phase III MAVERIC trial is a randomized, double-blind, placebo-controlled study that was more than 75% enrolled as of mid-2026. That trial, not this pilot, will determine whether CardiolRx earns a place in recurrent pericarditis treatment. Until those results are available, this Phase II data should be read as hypothesis-generating. Lens takeaway The controlled trial, not the pilot, will settle this. #### Orphan Drug Status Reflects Unmet Need, Not Proven Efficacy The FDA’s Orphan Drug Designation for CardiolRx in pericarditis reflects the seriousness of an underserved condition and supports continued development, not a determination that the drug works. That distinction matters for patients and clinicians who may see the designation and assume efficacy has already been established. Lens takeaway Orphan Drug status is about unmet need, not proof of benefit. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Massachusetts Clinical Care & Certification Are you a Massachusetts resident seeking physician-supervised cannabinoid therapy? Learn more about scheduling a telehealth consultation with a certified [Massachusetts medical marijuana doctor](https://cedclinic.com/massachusetts-medical-marijuana-doctor/), or read our step-by-step 2026 guide on [how to get a medical marijuana card in Massachusetts](https://cedclinic.com/how-to-get-a-medical-marijuana-card-in-massachusetts/) to save ~20% on state dispensary taxes. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=CBD+and+Recurrent+Pericarditis%3A+What+the+Phase+II+MAvERIC-Pilot+Trial+Shows&url=https%3A%2F%2Fcedclinic.com%2Fcbd-recurrent-pericarditis-maveric-pilot-trial%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcbd-recurrent-pericarditis-maveric-pilot-trial%2F) [BlueSky](https://bsky.app/intent/compose?text=CBD+and+Recurrent+Pericarditis%3A+What+the+Phase+II+MAvERIC-Pilot+Trial+Shows%20https%3A%2F%2Fcedclinic.com%2Fcbd-recurrent-pericarditis-maveric-pilot-trial%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Cardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association](https://www.cardiolrx.com/cardiol-therapeutics-phase-ii-maveric-results-accepted-for-publication-in-the-journal-of-the-american-heart-association/) Related Reading at CED Clinic Continue exploring the evidence [CBD Cardiovascular Evidence: What Research Actually Shows](https://cedclinic.com/cbd-and-cardiovascular-recovery-hrv-blood-pressure-dr-damas-cannabis/) A broader look at CBD’s cardiovascular effects, including heart rate variability and blood pressure, useful context for where this pericarditis trial fits. [Read the cardiovascular context](https://cedclinic.com/cbd-and-cardiovascular-recovery-hrv-blood-pressure-dr-damas-cannabis/) [CBD Neuroinflammation: What Clinical Evidence Shows](https://cedclinic.com/cbd-anti-inflammatory-neuroinflammation-effects-potential/) A companion look at CBD’s anti-inflammatory mechanisms, relevant to the NLRP3 inflammasome pathway discussed in the pericarditis trial. [Explore the mechanism](https://cedclinic.com/cbd-anti-inflammatory-neuroinflammation-effects-potential/) [Cannabis & Heart Attack Risk: Clinical Evidence](https://cedclinic.com/cannabis-users-face-substantially-higher-risk-of-heart-attack-2025/) An important counterpoint on cardiovascular risk associated with [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), useful for keeping pharmaceutical CBD and consumer cannabis products in separate clinical categories. [Read the risk data](https://cedclinic.com/cannabis-users-face-substantially-higher-risk-of-heart-attack-2025/) ## Frequently Asked Questions Is this the same CBD sold in dispensaries or wellness stores? No. CardiolRx is a pharmaceutical-grade, FDA Orphan Drug-designated oral CBD formulation manufactured and dosed under investigational protocol. It is not equivalent to commercially available CBD tinctures or gummies, which vary widely in purity, concentration, and regulatory oversight. Was this trial randomized or placebo-controlled? No. MAvERIC-Pilot was an open-label, single-arm Phase II study with no control group. That is the central limitation of this data, and it is why the sponsor is now running a randomized, double-blind, placebo-controlled Phase III trial, MAVERIC, before seeking regulatory approval. How many patients were in the study? Twenty-seven adults with symptomatic recurrent pericarditis, enrolled across eight U.S. clinical sites, with an average age of 53 and 67% female. Did the study show CBD reduced inflammation, or just pain? Both were reported. Average pain scores fell from 5.8 to 2.1 over 8 weeks, and 8 of the 10 patients who entered the trial with elevated C-reactive protein, an objective inflammation marker, had normal levels by week 8. Were there safety concerns? One patient experienced a serious adverse event that led to discontinuation of the trial medication. Researchers described the drug as otherwise safe and generally well tolerated in this small sample, but a larger controlled trial is needed to properly characterize risk. Who funded this research? Cardiol Therapeutics Inc., the manufacturer of CardiolRx, sponsored and ran the trial. This is disclosed here because industry sponsorship is a relevant factor in weighing the strength of the results, not because it invalidates them. Where was this published? Results were first presented at the American Heart Association Scientific Sessions 2024 as a Circulation abstract. Per the sponsor’s May 2026 press release, the full study was accepted for publication in the Journal of the American Heart Association; confirm the final citation directly on ahajournals.org before citing it elsewhere. What is the NLRP3 inflammasome, and why does it matter here? It is an intracellular inflammatory pathway thought to drive much of recurrent pericarditis. Pharmaceutical CBD has been shown in preclinical research to inhibit this pathway, which is the biological rationale for testing it in this disease. Does this mean CBD can replace colchicine or biologic therapy for pericarditis? No. This trial did not compare CBD head-to-head against colchicine or IL-1 inhibitors, and it should not be used to justify stopping established therapy without a larger, controlled trial confirming these results. What happens next? A pivotal, randomized, double-blind, placebo-controlled Phase III trial called MAVERIC is already underway and was more than 75% enrolled as of mid-2026. That trial will determine whether these Phase II results hold up under rigorous testing. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).